OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
OS Therapies IncorporatedAMEX: OSTX
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $124.94K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $362.39K. Over 3 fiscal years it compounded at +666.9% a year.
Context
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $124.94K or moves back toward the trailing-twelve-month quarterly average of $90.6K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 363.09K USD
- Year-over-year change
- +12960.6%
- 4-year CAGR
- -25.2%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 363.09K | +12960.6% |
| FY2024 | 2024-12-31 | 2.78K | -34.1% |
| FY2023 | 2023-12-31 | 4.22K | +424.2% |
| FY2022 | 2022-12-31 | 805 | -99.9% |
| FY2021 | 2021-12-31 | 1.16M | — |
Cost of Revenue vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's LTM Mar 2026 cost of revenue of $362.39K is the 5th highest of the 9 companies compared; the peer median is $303.04K.
- Its year-over-year change of +17280.8% is the 2nd highest of 6, against a peer median of +300.0%.
- Over three fiscal years its annual growth of +666.9% compares with a peer median of +34.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.85M | +242.5% | -13.3% | 13.6% | |
| LTM Mar 2026 | $1.54M | +977.1% | +54.6% | 460.9% | |
| LTM Mar 2026 | $1.44M | +35950.0% | +401.7% | 62.9% | |
| LTM Jun 2024 | $425.46K | — | — | 52.2% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $362.39K | +17280.8% | +666.9% | — |
| LTM Mar 2026 | $180.63K | +300.0% | — | 12.8% | |
| LTM Mar 2026 | $167.05K | -21.3% | +14.3% | — | |
| LTM Mar 2026 | $79K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding OSTX) | $303.04K | +300.0% | +34.4% | 52.2% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.16M | 805 | 4.22K | 2.78K | 363.09K |
| Gross Profit | (1.16M) | (805) | (4.22K) | (2.78K) | (363.09K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.17M | 3.29M | 3.22M | 2.84M | 16.36B |
| Selling, General & Admin | 1.5M | 1.15M | 1.12M | 3.97M | 12.34B |
| Operating Expenses | 3.68M | 4.45M | 4.34M | 6.81M | 28.34M |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09K |
| EBITDA | (4.84M) | (4.45M) | (4.34M) | (6.83M) | (28.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.84M) | (4.45M) | (4.34M) | (6.81M) | (28.71M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 249 |
| Interest Expense | 2.58M | 1.81M | 3.45M | 2.05M | 0 |
| Other Income / Expenses | (2.58M) | (1.81M) | (3.45M) | (2.07M) | (48.14K) |
| Income Before Tax | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| EPS (Diluted) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| Weighted Avg Shares | 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
| Weighted Avg Shares (Diluted) | 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.